Gilead ’s Vosevi receives FDA approval for re-treatment of chronic HCV
The US Food and Drug Administration (FDA) has approved biotechnology company Gilead Sciences ’ Vosevi (sofosbuvir at 400mg / velpatasvir at 100mg / voxilaprevir at 100mg) tablets for the re-treatment of chronic hepatitis C virus (HCV) infection.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Pharmaceuticals